Virus hunts liver tumors before chemo strikes

NCT ID NCT01171651

Completed Disease control Sponsor: Jennerex Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a cancer-killing virus called JX-594 (Pexa-Vec) in people with advanced liver cancer that cannot be removed by surgery. Participants receive the virus through an IV and then directly into liver tumors, followed by the standard drug sorafenib. The goal is to see if this combination is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JX-594 (Pexa-Vec), a cancer-killing virus, followed by sorafenib tablets
What this could lead to: If successful, this approach could offer a new way to treat advanced liver cancer by combining a virus that targets tumors with standard therapy.
What could go wrong: This is a small, early-phase safety study, so it may not show clear benefit. The virus can cause flu-like symptoms and other side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms vaccinia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

Contacts and locations

Show contact details

Locations

Pusan National University Hospital

Busan, South Korea
Pusan National University Yangsan Hospital

Yangsan, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.